Nawrocki ST - Search Results

1

Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.

Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS. Swords RT, et al. Among authors: nawrocki st. Blood. 2010 May 6;115(18):3796-800. doi: 10.1182/blood-2009-11-254862. Epub 2010 Mar 4. Blood. 2010. PMID: 20203261 Free article.

2

Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine.

Carew JS, Nawrocki ST, Xu RH, Dunner K, McConkey DJ, Wierda WG, Keating MJ, Huang P. Carew JS, et al. Among authors: nawrocki st. Leukemia. 2004 Dec;18(12):1934-40. doi: 10.1038/sj.leu.2403545. Leukemia. 2004. PMID: 15483672

3

Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Carew JS, Nawrocki ST, Krupnik YV, Dunner K Jr, McConkey DJ, Keating MJ, Huang P. Carew JS, et al. Among authors: nawrocki st. Blood. 2006 Jan 1;107(1):222-31. doi: 10.1182/blood-2005-05-1923. Epub 2005 Sep 6. Blood. 2006. PMID: 16144803 Free PMC article.

4

Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.

Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ. Nawrocki ST, et al. Cancer Res. 2005 Dec 15;65(24):11510-9. doi: 10.1158/0008-5472.CAN-05-2394. Cancer Res. 2005. PMID: 16357160

5

Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Dunner K Jr, Huang P, Abbruzzese JL, McConkey DJ. Nawrocki ST, et al. Cancer Res. 2005 Dec 15;65(24):11658-66. doi: 10.1158/0008-5472.CAN-05-2370. Cancer Res. 2005. PMID: 16357177

6

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr, Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ. Nawrocki ST, et al. Cancer Res. 2006 Apr 1;66(7):3773-81. doi: 10.1158/0008-5472.CAN-05-2961. Cancer Res. 2006. PMID: 16585204

7

Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.

Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL. Carew JS, et al. Among authors: nawrocki st. Blood. 2007 Jul 1;110(1):313-22. doi: 10.1182/blood-2006-10-050260. Epub 2007 Mar 15. Blood. 2007. PMID: 17363733 Free PMC article.

8

Modulating autophagy for therapeutic benefit.

Carew JS, Nawrocki ST, Cleveland JL. Carew JS, et al. Among authors: nawrocki st. Autophagy. 2007 Sep-Oct;3(5):464-7. doi: 10.4161/auto.4311. Epub 2007 Apr 19. Autophagy. 2007. PMID: 17495516

9

Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.

Nawrocki ST, Carew JS, Douglas L, Cleveland JL, Humphreys R, Houghton JA. Nawrocki ST, et al. Cancer Res. 2007 Jul 15;67(14):6987-94. doi: 10.1158/0008-5472.CAN-07-0812. Cancer Res. 2007. PMID: 17638911

10

Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.

Carew JS, Giles FJ, Nawrocki ST. Carew JS, et al. Among authors: nawrocki st. Cancer Lett. 2008 Sep 28;269(1):7-17. doi: 10.1016/j.canlet.2008.03.037. Epub 2008 May 6. Cancer Lett. 2008. PMID: 18462867 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters